Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zhejiang Hisun Pharmaceutical And Alpharma To Set Up Joint Venture

This article was originally published in PharmAsia News

Executive Summary

Zhejiang Hisun Pharmaceutical has signed an MOU with Alpharma API Hong Kong to set up a joint venture that produces and sells vancomycin. With a business term of 30 years, a total of $50 million will be allocated for the investment. Hisun will put up 49 percent of the $24.3 million paid-up capital. An informed source believes Hisun's real motivation in the venture is not to produce the low-profit vancomycin active pharmaceutical ingredients, but rather, to take advantage of Alpharma's international brandname and sales channels to market its own pharmaceutical preparations globally. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel